82 related articles for article (PubMed ID: 12447697)
1. The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway.
Kwong KY; Zou Y; Day CP; Hung MC
Oncogene; 2002 Nov; 21(54):8340-6. PubMed ID: 12447697
[TBL] [Abstract][Full Text] [Related]
2. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells.
Chen RH; McCormick F
Cancer Res; 2001 Jun; 61(11):4445-9. PubMed ID: 11389074
[TBL] [Abstract][Full Text] [Related]
3. Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway.
Dvory-Sobol H; Sagiv E; Liberman E; Kazanov D; Arber N
Cancer; 2007 Jan; 109(2):188-97. PubMed ID: 17149756
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of monocyte chemotactic protein-3 by activated beta-catenin.
Fujita M; Furukawa Y; Nagasawa Y; Ogawa M; Nakamura Y
Cancer Res; 2000 Dec; 60(23):6683-7. PubMed ID: 11118053
[TBL] [Abstract][Full Text] [Related]
5. Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells.
Roh H; Green DW; Boswell CB; Pippin JA; Drebin JA
Cancer Res; 2001 Sep; 61(17):6563-8. PubMed ID: 11522655
[TBL] [Abstract][Full Text] [Related]
6. Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts.
Green DW; Roh H; Pippin JA; Drebin JA
J Surg Res; 2001 Nov; 101(1):16-20. PubMed ID: 11676549
[TBL] [Abstract][Full Text] [Related]
7. beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.
Easwaran V; Lee SH; Inge L; Guo L; Goldbeck C; Garrett E; Wiesmann M; Garcia PD; Fuller JH; Chan V; Randazzo F; Gundel R; Warren RS; Escobedo J; Aukerman SL; Taylor RN; Fantl WJ
Cancer Res; 2003 Jun; 63(12):3145-53. PubMed ID: 12810642
[TBL] [Abstract][Full Text] [Related]
8. A mammalian two-hybrid system for adenomatous polyposis coli-mutated colon cancer therapeutics.
Wakita K; Tetsu O; McCormick F
Cancer Res; 2001 Feb; 61(3):854-8. PubMed ID: 11221869
[TBL] [Abstract][Full Text] [Related]
9. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers.
Vécsey-Semjén B; Becker KF; Sinski A; Blennow E; Vietor I; Zatloukal K; Beug H; Wagner E; Huber LA
Oncogene; 2002 Jul; 21(30):4646-62. PubMed ID: 12096341
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Kuroda T; Rabkin SD; Martuza RL
Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
[TBL] [Abstract][Full Text] [Related]
11. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
[TBL] [Abstract][Full Text] [Related]
12. Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas.
Souazé F; Viardot-Foucault V; Roullet N; Toy-Miou-Leong M; Gompel A; Bruyneel E; Comperat E; Faux MC; Mareel M; Rostène W; Fléjou JF; Gespach C; Forgez P
Carcinogenesis; 2006 Apr; 27(4):708-16. PubMed ID: 16299383
[TBL] [Abstract][Full Text] [Related]
13. Isolation of a novel human gene, APCDD1, as a direct target of the beta-Catenin/T-cell factor 4 complex with probable involvement in colorectal carcinogenesis.
Takahashi M; Fujita M; Furukawa Y; Hamamoto R; Shimokawa T; Miwa N; Ogawa M; Nakamura Y
Cancer Res; 2002 Oct; 62(20):5651-6. PubMed ID: 12384519
[TBL] [Abstract][Full Text] [Related]
14. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.
Verma UN; Surabhi RM; Schmaltieg A; Becerra C; Gaynor RB
Clin Cancer Res; 2003 Apr; 9(4):1291-300. PubMed ID: 12684397
[TBL] [Abstract][Full Text] [Related]
15. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC
Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908
[TBL] [Abstract][Full Text] [Related]
16. Target disruption of the mutant beta-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype.
Sekine S; Shibata T; Sakamoto M; Hirohashi S
Oncogene; 2002 Aug; 21(38):5906-11. PubMed ID: 12185590
[TBL] [Abstract][Full Text] [Related]
17. [beta-Catenin induces invasive growth by activating matrix metalloproteinases in colorectal carcinoma].
Brabletz T; Jung A; Dag S; Reu S; Kirchner T
Verh Dtsch Ges Pathol; 2000; 84():175-81. PubMed ID: 11217438
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy approach in prostate cancer cells using an active Wnt signal.
Giladi N; Dvory-Sobol H; Sagiv E; Kazanov D; Liberman E; Arber N
Biomed Pharmacother; 2007 Oct; 61(9):527-30. PubMed ID: 17904788
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex.
Shimokawa T; Furukawa Y; Sakai M; Li M; Miwa N; Lin YM; Nakamura Y
Cancer Res; 2003 Oct; 63(19):6116-20. PubMed ID: 14559787
[TBL] [Abstract][Full Text] [Related]
20. Identification of SP5 as a downstream gene of the beta-catenin/Tcf pathway and its enhanced expression in human colon cancer.
Takahashi M; Nakamura Y; Obama K; Furukawa Y
Int J Oncol; 2005 Dec; 27(6):1483-7. PubMed ID: 16273202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
